Utilization of coagulation assays in clinical therapeutics.

about

Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency.

P2860

Q53494094-E1CFF3A8-A208-46F7-BDAB-71C287BDF8C7

P2860

Utilization of coagulation assays in clinical therapeutics.

Item

http://www.wikidata.org/entity/Q38107905

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Utilization of coagulation assays in clinical therapeutics.

@en

type

Item

label

Utilization of coagulation assays in clinical therapeutics.

@en

prefLabel

Utilization of coagulation assays in clinical therapeutics.

@en

P1476

Utilization of coagulation assays in clinical therapeutics.

@en

P2093

Goldie L Peters

http://www.w3.org/2001/XMLSchema#string

Matthew K Pitlick

http://www.w3.org/2001/XMLSchema#string

P Benjamin Erwin

http://www.w3.org/2001/XMLSchema#string

Zachary A Stacy

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Clinical utilization of the international normalized ratio (INR).

Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic

Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.

Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring.

Monitoring the new antithrombotic drugs.

How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults.

Oral anticoagulant drugs.

P304

1214-1222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1283

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236921266

http://www.w3.org/2001/XMLSchema#string

P698

23686890

http://www.w3.org/2001/XMLSchema#string

Utilization of coagulation assays in clinical therapeutics.

about

P2860

P2860

Utilization of coagulation assays in clinical therapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698